BM 15.075对不同类型高脂蛋白血症患者脂蛋白浓度的影响。

Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.

作者信息

Olsson A G, Rössner S, Walldius G, Carlson L A, Lang P D

出版信息

Atherosclerosis. 1977 Jul;27(3):279-87. doi: 10.1016/0021-9150(77)90037-5.

Abstract

The four-week lipoprotein lowering effect of 0.2 g t.i.d. of BM 15.075 and of 0.5 g t.i.d. of clofibrate was studied in 29 subjects with different types of hyperlipoproteinaemia in a single blind crossover fashion. BM 15.075 decreased very low density lipoproteins (VLDL), triglycerides (TG) and cholesterol concentration in all types of hyperlipoproteinaemia the effect being dependent on initial lipoprotein concentrations. BM 15.075 decreased VLDL triglyceride concentrations on average 20% more than did clofibrate. BM 15.075 decreased low density lipoproteins (LDL) cholesterol concentrations in Type IIA and IIB but did not significantly affect this lipoprotein lipid in type IV hyperlipoproteinaemia. Regression analysis showed that the drug tended to decrease LDL cholesterol if initial concentrations were above 157 mg/100 ml and to increase initially lower levels. No significant differences between BM 15.075 and clofibrate was found in the effect of LDL cholesterol. High density lipoproteins (HDL) cholesterol concentrations were not influenced by BM 15.075. No subjective side effects were noted on BM 15.075. S-ASAT increased and alcaline phosphatases decreased on both treatments.

摘要

采用单盲交叉方式，对29例不同类型高脂蛋白血症患者研究了每日3次服用0.2 g BM 15.075和每日3次服用0.5 g氯贝丁酯的四周降脂效果。BM 15.075可降低所有类型高脂蛋白血症患者的极低密度脂蛋白（VLDL）、甘油三酯（TG）和胆固醇浓度，其效果取决于初始脂蛋白浓度。BM 15.075使VLDL甘油三酯浓度降低的幅度平均比氯贝丁酯多20%。BM 15.075可降低IIA型和IIB型患者的低密度脂蛋白（LDL）胆固醇浓度，但对IV型高脂蛋白血症患者的这种脂蛋白脂质无显著影响。回归分析表明，如果初始浓度高于157 mg/100 ml，该药倾向于降低LDL胆固醇，而使初始较低水平升高。在降低LDL胆固醇的效果方面，未发现BM 15.075与氯贝丁酯之间存在显著差异。BM 15.075对高密度脂蛋白（HDL）胆固醇浓度无影响。未观察到BM 15.075有主观副作用。两种治疗均使血清谷草转氨酶升高，碱性磷酸酶降低。